<\/p>\n
Rivamer<\/strong> is an oral capsule from Sun Pharma containing rivastigmine 1.5 mg<\/strong> — a dual acetylcholinesterase + butyrylcholinesterase inhibitor<\/strong> used for the symptomatic treatment of mild til moderat Alzheimers sykdom<\/strong> AND Parkinson's disease dementia<\/strong> (the only AChE inhibitor licensed for PDD). Slow titration: 1.5 mg twice daily for 2 weeks → 3 mg twice daily for 2 weeks → 4.5 mg twice daily for 2 weeks → 6 mg twice daily maintenance<\/strong>. Always take with food.<\/strong> The transdermal patch (not stocked here) significantly reduces GI side effects and is preferred for patients who cannot tolerate the oral form.<\/p>\n<\/div>\n \ud83d\udce6 Hver ordre er dekket av v\u00e5r Reshipment Assurance Policy<\/strong><\/a> \u2014 hvis pakken din ikke ankommer innen 20 virkedager, sender vi ny.<\/p>\n V\u00e5re generiske legemidler kommer fra WHO-GMP-sertifiserte produsenter og sendes over hele verden i diskret, n\u00f8ytral emballasje \u2014 ingen legemiddelnavn p\u00e5 utsiden av pakken. Kortbetalinger h\u00e5ndteres av en regulert betalingsbehandler (kontoutskrifter viser en regulert kortbetalingsprosessor \u2014 aldri \u201cMedsBase\u201d eller noe legemiddelnavn). Krypto og SEPA bankoverf\u00f8rsel godtas ogs\u00e5. Hver ordre er dekket av v\u00e5r Reshipment Assurance Policy.<\/p>\n Rivamer is an oral capsule from Sun Pharma containing rivastigmine tartrate 1.5 mg<\/strong>. Rivastigmine is a pseudo-irreversible dual cholinesterase inhibitor<\/strong> — it inhibits both acetylcholinesterase (AChE)<\/strong> og butyrylcholinesterase (BuChE)<\/strong>. The dual mechanism distinguishes it from donepezil and galantamine, which only inhibit AChE.<\/p>\n Rivamer from Sun Pharma is a 1.5 mg rivastigmine capsule — the starting dose for the 6–8 week titration in mild-to-moderate Alzheimer's and Parkinson's disease dementia. Titrate to the maintenance 12 mg\/day dose. Always take with food to minimise the GI side effects that are characteristic of oral rivastigmine. Rivastigmine is the only cholinesterase inhibitor with a licensed indication for Parkinson's disease dementia<\/strong> in addition to mild-to-moderate Alzheimer's. The dual ACh + BuChE inhibition may matter more in PDD because BuChE activity is relatively preserved in PD compared with Alzheimer's.<\/p>\n Both Alzheimer's disease and Parkinson's disease dementia involve cholinergic neuron loss. Rivastigmine raises synaptic acetylcholine through dual enzymatic inhibition:<\/p>\n Start p\u00e5 kognitiv nytte: synlig ved 6\u201312 uker<\/strong> on the maintenance 9–12 mg\/day dose; peak at 6 months.<\/p>\n Rivamer is ikke<\/strong> indicated for: severe Alzheimer's disease (only donepezil is licensed at this stage), mild cognitive impairment, frontotemporal dementia (worsens behavioural symptoms), or as a cognitive enhancer in healthy adults.<\/p>\n Rivamer comes at 1,5 mg<\/strong> capsules. The 6–8 week titration is mandatory — rivastigmine has the most aggressive GI profile of all AChE inhibitors when given orally.<\/p>\n Standard 6–8 week titration:<\/strong><\/p>\n Common (highest GI burden of all oral AChE inhibitors):<\/strong><\/p>\n Mindre vanlig, men viktig:<\/strong><\/p>\n Rare but seek medical attention:<\/strong><\/p>\nHvorfor bestille fra MedsBase<\/h3>\n
What Is Rivamer?<\/h2>\n
How Does Rivamer Work?<\/h2>\n
\n
Bruk og indikasjoner<\/h2>\n
\n
Rivamer Dosage and How to Take — SLOW TITRATION<\/h2>\n
\n
How to Take Rivamer Properly<\/h3>\n
\n
Side Effects of Rivamer<\/h2>\n
\n
\n
\n
Advarsler og forholdsregler<\/h2>\n
\n
Contraindications — Who Should NOT Take Rivamer<\/h2>\n
\n
Legemiddelinteraksjoner<\/h2>\n